Skip to main content
Top
Published in: Breast Cancer Research 1/2021

01-12-2021 | Breast Cancer | Research article

Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study

Authors: Lindsay J. Collin, Maret L. Maliniak, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Kristina B. Christensen, Sinna P. Ulrichsen, Per Damkier, Stephen Hamilton-Dutoit, Rami Yacoub, Peer M. Christiansen, Henrik Toft Sørensen, Timothy L. Lash

Published in: Breast Cancer Research | Issue 1/2021

Login to get access

Abstract

Background

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that facilitates the adaptation of cancer cells to hypoxic conditions and may be prognostic of breast cancer recurrence. We evaluated the association of HIF-1α expression with breast cancer recurrence, and its association with timing of breast cancer recurrence.

Methods

In this population-based case-control study, we included women diagnosed with stage I–III breast cancer between 1985 and 2001, aged 35–69 years, registered in the Danish Breast Cancer Group. We identified 541 cases of breast cancer recurrence among women with estrogen receptor (ER)-positive disease who were treated with tamoxifen for at least 1 year (ER+ TAM+). We also enrolled 300 breast cancer recurrence cases among women with ER-negative disease, not treated with tamoxifen, who survived at least 1 year (ER−/TAM−). Controls were recurrence-free breast cancer patients at the time of case diagnosis, matched to recurrence cases on ER/TAM status, date of surgery, menopausal status, cancer stage, and county of residence. Expression of HIF-1α was measured by immunohistochemistry on tissue microarrays. We fitted logistic regression models to compute odds ratios (ORs) and 95% confidence intervals (CIs) associating HIF-1α expression with recurrence, and with timing of recurrence.

Results

HIF-1α expression was observed in 23% of cases and 20% of controls in the ER+/TAM+ stratum, and in 47% of cases and 48% of controls in the ER−/TAM− stratum. We observed a near-null association between HIF-1α expression in both ER/TAM groups (ER+/TAM+ OR = 1.21, 95%CI 0.88, 1.67 and ER−/TAM− OR = 0.97, 95%CI 0.68, 1.39). HIF-1α expression was not associated with time to recurrence among women in the ER+/TAM+ stratum, but was associated with early recurrence among women in the ER−/TAM− stratum.

Conclusion

In this study, HIF-1α expression was not associated with breast cancer recurrence overall but may be associated with early recurrence among women diagnosed with ER− breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Sauer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.CrossRef DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Sauer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.CrossRef
2.
go back to reference Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46.CrossRef Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46.CrossRef
3.
go back to reference Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927–35.CrossRef Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927–35.CrossRef
4.
go back to reference Syrowatka A, Motulsky A, Kurteva S, Hanley JA, Dixon WG, Meguerditchian AN, et al. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat. 2017;165(2):229–45.CrossRef Syrowatka A, Motulsky A, Kurteva S, Hanley JA, Dixon WG, Meguerditchian AN, et al. Predictors of distress in female breast cancer survivors: a systematic review. Breast Cancer Res Treat. 2017;165(2):229–45.CrossRef
5.
go back to reference Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551–78.CrossRef Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551–78.CrossRef
6.
go back to reference Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.CrossRef Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.CrossRef
7.
go back to reference Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. JNCI J Natl Cancer Inst. 2001;93(4):309–14.CrossRef Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. JNCI J Natl Cancer Inst. 2001;93(4):309–14.CrossRef
8.
go back to reference Dales J-P, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut M-N, et al. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer. 2005;116(5):734–9.CrossRef Dales J-P, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut M-N, et al. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. Int J Cancer. 2005;116(5):734–9.CrossRef
9.
go back to reference Zhong H, Marzo AMD, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5.PubMed Zhong H, Marzo AMD, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5.PubMed
10.
go back to reference Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, et al. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol. 2015;41(2):e41-55.CrossRef Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, et al. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol. 2015;41(2):e41-55.CrossRef
11.
go back to reference Sonveaux P, Copetti T, Saedeleer CJD, Végran F, Verrax J, Kennedy KM, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE. 2012;7(3):e33418.CrossRef Sonveaux P, Copetti T, Saedeleer CJD, Végran F, Verrax J, Kennedy KM, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE. 2012;7(3):e33418.CrossRef
12.
go back to reference Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. JNCI J Natl Cancer Inst. 2011;103(6):489–500.CrossRef Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. JNCI J Natl Cancer Inst. 2011;103(6):489–500.CrossRef
13.
go back to reference Jensen M-B, Laenkholm A-V, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018;57(1):13–8.CrossRef Jensen M-B, Laenkholm A-V, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol. 2018;57(1):13–8.CrossRef
14.
go back to reference Christiansen P, Al-Suliman N, Bjerre K, Møller S. Recurrence pattern and prognosis in low-risk breast cancer patients: data from the DBCG 89-A programme. Acta Oncol. 2008;47(4):691–703.CrossRef Christiansen P, Al-Suliman N, Bjerre K, Møller S. Recurrence pattern and prognosis in low-risk breast cancer patients: data from the DBCG 89-A programme. Acta Oncol. 2008;47(4):691–703.CrossRef
15.
go back to reference Rothman KJ, Greenland S, Lash TL. Modern epidemiology, 3rd edition. Lippincott Williams & Wilkins. Rothman KJ, Greenland S, Lash TL. Modern epidemiology, 3rd edition. Lippincott Williams & Wilkins.
16.
go back to reference Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.CrossRef Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.CrossRef
17.
go back to reference Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;9(2):51–6.CrossRef Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;9(2):51–6.CrossRef
18.
go back to reference McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–21.PubMed McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–21.PubMed
19.
go back to reference Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRef Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–95.CrossRef
20.
go back to reference Efron B. Nonparametric estimates of standard error: the Jackknife, the bootstrap and other methods. Biometrika. 1981;68(3):589–99.CrossRef Efron B. Nonparametric estimates of standard error: the Jackknife, the bootstrap and other methods. Biometrika. 1981;68(3):589–99.CrossRef
21.
go back to reference Wang W, He Y-F, Sun Q-K, Wang Y, Han X-H, Peng D-F, et al. Hypoxia-inducible factor 1α in breast cancer prognosis. Clin Chim Acta. 2014;20(428):32–7.CrossRef Wang W, He Y-F, Sun Q-K, Wang Y, Han X-H, Peng D-F, et al. Hypoxia-inducible factor 1α in breast cancer prognosis. Clin Chim Acta. 2014;20(428):32–7.CrossRef
22.
go back to reference Kronblad Å, Jirström K, Rydén L, Nordenskjöld B, Landberg G. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer. 2006;118(10):2609–16.CrossRef Kronblad Å, Jirström K, Rydén L, Nordenskjöld B, Landberg G. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer. 2006;118(10):2609–16.CrossRef
23.
go back to reference Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394(6692):485–90.CrossRef Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394(6692):485–90.CrossRef
24.
go back to reference Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol Baltim Md. 2002;16(10):2231–42.CrossRef Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol Baltim Md. 2002;16(10):2231–42.CrossRef
25.
go back to reference Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: american society of clinical oncology guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(25):3069–103.CrossRef Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: american society of clinical oncology guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(25):3069–103.CrossRef
26.
go back to reference Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, et al. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol. 2014;53(4):433–44.CrossRef Christiansen P, Vejborg I, Kroman N, Holten I, Garne JP, Vedsted P, et al. Position paper: breast cancer screening, diagnosis, and treatment in Denmark. Acta Oncol. 2014;53(4):433–44.CrossRef
27.
go back to reference Møller S, Jensen M-B, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–24.CrossRef Møller S, Jensen M-B, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–24.CrossRef
Metadata
Title
Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study
Authors
Lindsay J. Collin
Maret L. Maliniak
Deirdre P. Cronin-Fenton
Thomas P. Ahern
Kristina B. Christensen
Sinna P. Ulrichsen
Per Damkier
Stephen Hamilton-Dutoit
Rami Yacoub
Peer M. Christiansen
Henrik Toft Sørensen
Timothy L. Lash
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-021-01480-1

Other articles of this Issue 1/2021

Breast Cancer Research 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine